Top image

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

Article Type
News Articles
12 October 2016

Published online 1 September 2017 in the Lancet were results of a first-in-man study of TargomiRs. The study showed that a dose of 5 × 10⁹ TargomiRs per week was well tolerated and was accompanied by early signs of antitumour activity. This study provides important safety data and shows encouraging response and survival in patients with malignant pleural mesothelioma. 

Full text available here, with permission of fellow Sydney Catalyst member Nico van Zandwijk, ADRI.

Back to list